Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Id 41,

Poster Exhibitions

Tuesday July 9

TuPeB46o3 Virologic response to ritonavir-boosted Indinavir
regimens correlates with baseline phenotypic
resistance to Indinavir
H Rice, A Zolopa, M Horberg, D Klein, M Coram,
J H Condra, N Hellmann, H King, M Bates
(United States)
TuPeB46o4 Lopinavir+Abacavir+Stavudina in the salvage
treatment of multitreated HIV patients with
failures to multiples previous antivirals
F GM Feregrino-Govos, A D R Alvarado-Diez
Rocio, R CO0 Ruiz-Campos Omar., G C H GomezCaro Humberto (Mexico)
TuPeB46o5 High prevalence of multi-drug resistance
mutations in Thai patients treated for prolonged
period with double nucleosides
S SirivichaVakul K Ruxrungtham, C Sa-nguansilp,
P Phanupiak (Thailand)
TuPeB46o6 A case report of levofloxacin resistance in an H IV
patient with Streptococcus Pneumoniae
pneumonia
S H Kasperbauer B Young, P Smith, D Bartelt
(United States)
TuPeB46o7 Frequency of drug-resistant mutations among
HIV-1C infected drug-naive patients in Botswana
H Bussmann', V Novitsky2, W Wester', K Masupul,
V Chipfakacha', WJimbo', S Gaolekwe',
R Marlink2, T Peter', I Thior', M Essex2
('Botswana; 2United States)
TuPeB46o8 Detection of different patterns of multiresistance
to reverse transcriptase (RT) and protease (PR)
inhibitors in HIV-1 infected persons from Pais
Vasco (Spain)
R Carmona L Perez-Alvarez, M L Villahermosa,
L Medrano, G Cilla, JA Iribarren, M J Lopez,
J Mayo, J Corral, K Aguirrebengoa, A Labora,
A Andia, J M Santamarfa, M D Suarez-Fernandez,
R Najera (Spain)
TuPeB46o9 HIV-1 drug resistance genotype interpretation:
how to establish and maintain an algorithm
CL Reid', D L Winslow', K Smith', J D Baxter2,
F Brun-Vezinet3, B Clotet4, R M Grant2,
C Loveday5, T C Merigan2, W O'Brien2,
MA Wainberg', J M Schapiro2 (Canada; 2United
States; 3France; 4Spain; 5United Kingdom)
TuPeB461o Comparative analysis of different algorithms for
the interpretation of HIV-1 drug resistance
genotype
I Zapiola, S Kaufman, C Zala, P Cahn, M B Bouzas
(Argentina)
TuPeB4611 Transmitted HIV-1 reverse transcriptase inhibitor
resistance mutation stability in ART-naive recent
seroconverters: results of the polaris HIV
seroconversion study
R Pilon, P Sandstrom, A Burchell, L Calzavara,
C Major, S Read, K Logue, M Ostrowski, K Gough,
A Rachlis (Canada)
TuPeB4612 In vitro studies reveal that zidovudine accelerates
the reversion of nevirapine and lamivudine
resistance confering mutations in the rt gene.
K Diallo, B Brenner, M Oliveira, D Moisi, M Goette,
MA Wainberg (Canada)
TuPeB4613 Mutations in H IV-i protease associated with
resistance to amprenavir contribute towards
phenotypic resistance to lopinavir
NT Parkin, C Chappey, C ] Petropoulos
(United States)

TuPeB4614 Classical subtype B resistance mutations and novel
candidate non-subtype B resistance mutations in
treated persons with non-B HIV-i isolates
R Kantor', D Katzenstein', PA Cane2, L Morris3,
J Snoeck4, A M Vandamme4, C Pillay3, D Pillay2,
J M Schapiro', R W Shafer' (United States;
2United Kingdom; 3South Africa; 4Belgium)
TuPeB4615 Effects of granulocyte/monocyte apheresis in
HAART resistant patients: down-modulation of
chemokine receptors CXCR3 and CXCR4 and
maintenance of CD4 T cell counts during the drug
holiday intervals
A Beretta (Italy)
TuPeB4616 Enhanced performance of a HIV-1 genotyping
assay due to RNA denaturation performed prior
to reverse transcription
D Vlobes, 0 Petrauskene, A ] Devitt, VT Nguyen,
K Kunstman, R C Brown, M R Furtado
(United States)
TuPeB4617 Mycobacterium tuberculosis sensitivity to
antituberculous drugs in HIV-positive patients
P Mugabo (South Africa)
TuPeB4618 Differences in resistance genotype interpretations
M Campodonico, G Avalle, S Benetti, 0 Fay, F Fay
(Argentina)
TuPeB4619 Prevalence and pattern of genotypic resistance in
a cohort of 500oo patients starting triple
antiretroviral therapy
MA Garcfa-Viejo, M I Perez-Elfas, A Moreno,
I Garcia-Arata, E Bermddez, V Mufioz, C Gutierrez,
Y Martin, D L6pez, S Moreno (Spain)
TuPeB462o Antiretroviral drug resitance mutations in HIV-1
infected patients from Salvador, Bahia, Brasil
V 0 G olavarria, JS Spinola, C B Brites,
B G Galvdo, NS Shindo (Brazil)
TuPeB4621 Variables associated with virological response in
HIV patients treated with rescue regimens guided
by genotypic resistance test (GRT)
E Fumero E Ferrer, M l Barbera, ] L Perez,
B Roson, M Santin, D Podzamczer (Spain)
TuPeB4622 An approach to estimate in vivo replicative
fitness in the presence of antivirals
B Yip, A Weber PR Harrigan, JS G Montaner
(Canada)
TuPeB4623 Genotypic analysis of the protease and reverse
transcriptase of HIV-1 subtype C isolates from
untreated patients in Malawi
LA Petch', I F Hoffman', CS Jere2, P N Kazembe2,
FE Martinson', D Chilongozi', M S Cohen',
S A Fiscus' (United States; 2Malawi)
TuPeB4624 A prospective randomized study on the
usefulness of Genotypic Resistance Tests versus
real Phenotypic Resistance Tests in heavily
pretreated patients with virological failure
(VI H RES Study)
I L Blanco, G Valdecillos, I R Arroyo, E De Lazari,
A Guelar, P Domingo, H Knobel, I M Gatell (Spain)
TuPeB4625 Triple nucleoside analogue therapy with
Zidovudine (AZT), Lamivudine (3TC) and Abacavir
(ABC) in the Paediatric H IV London South
Network (PHILS-NET) cohort
C Wells M Sharland, CI Smith, G Du Mont,
CS Ball, FA I Riordan, H C Underhill
(United Kingdom)
TuPeB4626 1 year follow up of salvage therapy (ST) with
lopinavir/ritonavir and amprenavir based
combinations in children failing previous highly

active anti-retroviral therapy (HAART) regimens
M Mathur E Handelsman, K Tizer, N Desai
(United States)
XIV International AIDS Conference BARCELONA - JULY 7-12

Tuesday

101